A type of localised scleroderma known as morphea. Credit: Leith C Jones at English Wikipedia.

Emerald Health Pharmaceuticals (EHP) has started patient enrolment for its Phase I clinical trial of EHP-101 for the treatment of patients with multiple sclerosis (MS) and scleroderma.

The randomised, double-blind, placebo-controlled trial is being carried out in Australia.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It will be conducted in two parts: a single-ascending dose phase (Part 1) and a multiple-ascending dose phase (Part 2).

During the first phase of the trial, the company is expected to enrol up to 64 healthy subjects who will receive EHP-101 or placebo in single-ascending oral doses.

A maximum of 40 healthy subjects will be included in the second phase and will be administered EHP-101 or placebo in multiple-ascending daily oral doses, as determined in Part 1.

The trial’s primary endpoints are to evaluate the safety and tolerability of EHP-101.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“We believe our novel, proprietary oral treatment represents a significant advancement in the treatment of patients with multiple sclerosis (MS) and scleroderma.”

Its secondary endpoints include evaluation of the pharmacokinetic profile, food effects, and pharmacodynamic effects of EHP-101, as well as various biomarkers related to EHP-101’s mechanism of action and its potential for efficacy.

Top-line results from the trial are expected to be published next year.

Emerald Health Pharmaceuticals CEO Jim DeMesa said: “Our research and development team has demonstrated the unique mechanism of action of EHP-101 in preclinical studies, indicating the potential to treat deadly diseases which currently have no cure.

“We believe our novel, proprietary oral treatment represents a significant advancement in the treatment of patients with multiple sclerosis (MS) and scleroderma.

“The initiation of human studies is a major accomplishment as we continue to advance cannabinoid science and deliver on another important development milestone. Based on our recent pre-IND meeting with the US FDA, we believe the results from this Phase I study are likely to support Phase II studies in both MS and scleroderma.”

EHP-101 is an investigational oral drug formulation of a synthetic new chemical entity (NCE) derived from cannabidiol (CBD).

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
YPrime won the Innovation award for AI in Clinical Trials and the Environmental award for Sustainable Trials, thanks to its eCOA, IRT and eConsent platforms. Explore how purpose-built AI, paperless workflows and circular hardware practices are reshaping timelines, data quality and ESG performance in clinical research.

Discover the Impact